iBio Establishes Oncology Drug Discovery Pipeline with Three New Antibody Programs
July 08 2021 - 4:15PM
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech
innovator and biologics contract manufacturing organization, has
taken another major step towards leveraging the speed and
throughput of its proprietary, plant-based
FastPharming Protein Expression System® by
announcing today it is adding three anti-cancer targets to its
pipeline of therapeutic candidates. This development establishes
the Company’s new drug discovery capabilities announced just a few
weeks ago.
As part of iBio's efforts to change the drug
development paradigm with the FastPharming System
by reducing the time and cost to move from initial concept to the
clinic, the Company intends to partner with best-in-class
technology partners to help achieve that vision. Accordingly, iBio
has entered into a research services agreement with FairJourney
Biologics S.A. (“FairJourney”), leaders in antibody optimization.
Pursuant to the agreement, iBio will gain access to novel display
technologies and proprietary antibody libraries.
“We believe combining our ‘speed-to-clinic’
advantages and Glycaneering TechnologiesTM with
the antibody optimization technologies provided by FairJourney may
enable us to quickly develop differentiated cancer therapeutic
antibodies with improved antibody-dependent cell-mediated
cytotoxicity, or ADCC,” said Martin B. Brenner, DVM, Ph.D., iBio’s
Chief Scientific Officer.
António Parada, CEO at FairJourney commented,
“Our experience in antibody discovery for use in oncology has grown
in recent years, with a number of undisclosed collaborations
rapidly moving towards the clinic. We are excited to work with an
innovator like iBio, which we believe has the ability to change the
bioprocess paradigm, using its proprietary glycosylation
technologies to enhance human anti-cancer antibody
development.”
About FairJourney Biologics
S.A.
FairJourney is a leading biologics CRO,
providing integrated services across antibody discovery,
engineering and production to global biopharma. Founded in 2012 and
headquartered in Porto, Portugal, FairJourney has grown to over 130
highly technically skilled employees today. The Company operates a
flexible, customer-oriented ‘one-stop shop’ approach to biologics
development focused on quality, reliability and partnership.
FairJourney has successfully completed more than 500 projects for
over 100 customers across big pharma and leading biotech companies
to date. The Company’s significant expertise in phage display
technology, combined with a diverse approach to generating both
immune and naïve antibody libraries, have contributed to a market
leading 99%+ project success rate. For more information, please
visit http://fjb.pt.
About iBio, Inc.
iBio is a global leader in plant-based biologics
manufacturing. Its FastPharming System® combines
vertical farming, automated hydroponics, and novel glycosylation
technologies to rapidly deliver high-quality monoclonal antibodies,
vaccines, bioinks and other proteins. iBio is developing
proprietary products which include biopharmaceuticals for the
treatment of cancers, as well as fibrotic and infectious diseases.
The Company’s subsidiary, iBio CDMO LLC, provides
FastPharming Contract Development and
Manufacturing Services along with Glycaneering
Development Services™ for advanced recombinant protein design. For
more information, visit www.ibioinc.com.
FORWARD-LOOKING STATEMENTS
Certain statements in this press release
constitute "forward-looking statements" within the meaning of the
federal securities laws. Words such as "may," "might," "will,"
"should," "believe," "expect," "anticipate," "estimate,"
"continue," "predict," "forecast," "project," "plan," "intend" or
similar expressions, or statements regarding intent, belief, or
current expectations, are forward-looking statements. These
forward-looking statements are based upon current estimates and
assumptions and include statements regarding the contributions of
FairJourney Biologics to the Company’s oncology drug discovery
program, achieving the Company’s vision of reducing the time and
cost to move from initial concept to the clinic by using the
Company’s FastPharming System® and partnering with
best-in-class service providers, enabling the Company to quickly
develop differentiated cancer therapeutic antibodies with improved
antibody-dependent cell-mediated cytotoxicity, or ADCC, by
combining the Company’s ‘speed-to-clinic’ advantages and
Glycaneering TechnologiesTM with the antibody
optimization technologies provided by FairJourney, and the Company
changing the bioprocess paradigm using the Company’s proprietary
glycosylation technologies to enhance human anti-cancer antibody
development. While the Company believes these forward-looking
statements are reasonable, undue reliance should not be placed on
any such forward-looking statements, which are based on information
available to us on the date of this release. These forward-looking
statements are subject to various risks and uncertainties, many of
which are difficult to predict that could cause actual results to
differ materially from current expectations and assumptions from
those set forth or implied by any forward-looking statements.
Important factors that could cause actual results to differ
materially from current expectations include, among others,
contributions of FairJourney to the Company’s oncology drug
discovery program, the Company’s ability to reduce the time and
cost to move from initial concept to the clinic by using its
FastPharming System and partnering with
best-in-class service providers , the ability to quickly develop
differentiated cancer therapeutic antibodies with improved
antibody-dependent cell-mediated cytotoxicity, or ADCC, by
combining the Company’s ‘speed-to-clinic’ advantages and
Glycaneering Technologies with the antibody
optimization technologies provided by FairJourney, the ability to
enhance human anti-cancer antibody development by using the
Company’s proprietary glycosylation technologies, the Company’s
ability to obtain regulatory approvals for commercialization of its
product candidates, or to comply with ongoing regulatory
requirements, regulatory limitations relating to its ability to
promote or commercialize its product candidates for specific
indications, acceptance of its product candidates in the
marketplace and the successful development, marketing or sale of
products, its ability to maintain its license agreements, the
continued maintenance and growth of its patent estate, its ability
to establish and maintain collaborations, its ability to obtain or
maintain the capital or grants necessary to fund its research and
development activities, competition, its ability to retain its key
employees or maintain its NYSE American listing, and the other
factors discussed in the Company’s Annual Report on Form 10-K for
the year ended June 30, 2020 and the Company’s subsequent filings
with the SEC, subsequent periodic reports on Forms 10-Q and 8-K.
The information in this release is provided only as of the date of
this release, and we undertake no obligation to update any
forward-looking statements contained in this release on account of
new information, future events, or otherwise, except as required by
law.
Contact:
Stephen KilmeriBio, Inc.Investor Relations(646)
274-3580skilmer@ibioinc.com
iBio (AMEX:IBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
iBio (AMEX:IBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024